Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic)

被引：0
|
作者：
Mohamed Hamidou
Antoine Néel
Joel Poupon
Zahir Amoura
Mikael Ebbo
Jean Sibilia
Jean-Francois Viallard
Benjamin Gaborit
Christelle Volteau
Jean Benoit Hardouin
Eric Hachulla
François Rieger
机构：
[1] Department of Internal Medicine,Department of Biological Toxicology
[2] CHU Nantes,Department of Internal Medicine 2, Centre National de Référence pour le Lupus, Institut E3M
[3] Nantes Université,Service de Médecine Interne
[4] AP-HP,Department of Rheumatology
[5] Lariboisière Hospital,Department of Internal Medicine
[6] University Paris VII,Plateforme de Méthodologie et Biostatistiques, CHU Nantes
[7] Hôpital Pitié-Salpétrière,Department of Internal Medicine, Centre de Référence des Maladies Autoimmunes Systémiques Rares du Nord et Nord
[8] Aix Marseille Univ,Ouest de France (CeRAINO)
[9] APHM,undefined
[10] CNRS,undefined
[11] INSERM,undefined
[12] CIML,undefined
[13] Hôpital de la Timone,undefined
[14] University of Strasbourg,undefined
[15] Haut-Lévêque University Hospital,undefined
[16] Université de Nantes,undefined
[17] INSERM UMR 1246-SPHERE,undefined
[18] Université de Nantes,undefined
[19] University of Lille,undefined
[20] MEDSENIC,undefined
[21] SAS,undefined
[22] a company with CNRS participation,undefined
来源：
Arthritis Research & Therapy | / 23卷
关键词：
Systemic lupus erythematosus; Autoimmune diseases; Treatment; Arsenic trioxide; Phase II clinical trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
    He, Jing
    Zhang, Ruijun
    Shao, Miao
    Zhao, Xiaozhen
    Miao, Miao
    Chen, Jiali
    Liu, Jiajia
    Zhang, Xiaoying
    Zhang, Xia
    Jin, Yuebo
    Wang, Yu
    Zhang, Shilei
    Zhu, Lei
    Jacob, Alexander
    Jia, Rulin
    You, Xujie
    Li, Xue
    Li, Chun
    Zhou, Yunshan
    Yang, Yue
    Ye, Hua
    Liu, Yanying
    Su, Yin
    Shen, Nan
    Alexander, Jessy
    Guo, Jianping
    Ambrus, Julian
    Lin, Xin
    Yu, Di
    Sun, Xiaolin
    Li, Zhanguo
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (01) : 141 - 149
  • [32] An open-label, multicenter, noncomparative safety and efficacy study of Mircette™, a low-dose estrogen-progestin oral contraceptive
    Akin, M
    Archer, D
    Berga, S
    Burns, L
    Calkins, J
    Davis, A
    Draeger, M
    Freidensen, H
    Funk, S
    Giesler, C
    Gordon, S
    Katz, D
    Khairi, S
    Ledger, W
    Lenihan, J
    London, R
    McQuarrie, H
    Medina, H
    Mercer, L
    Milhalov, L
    Montgomery, M
    Notelovitz, M
    Parker, G
    Phillips, E
    Reza, L
    San Fillippo, J
    Saxena, B
    Singh, M
    Soltes, B
    Soper, H
    Speroff, L
    Summers, P
    Trupin, S
    Weissberg, S
    Willems, J
    Young, R
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1998, 179 (01) : S2 - S8
  • [33] SAFETY OF SUBCUTANEOUS BELIMUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A 6-MONTH OPEN-LABEL EXTENSION STUDY
    Doria, A.
    Stohl, W.
    Schwarting, A.
    Scheinberg, M.
    Hammer, A.
    Kleoudis, C.
    Groark, J.
    Fox, N. L.
    Roth, D.
    Bass, D.
    Gordon, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 861 - 861
  • [34] EFFECT OF GENETIC POLYMORHISMS ON THE EFFICACY OF LOW-DOSE AZATHIOPRINE THERAPY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Aomori, T.
    Nagamine, A.
    Takenaka, M.
    Okada, Y.
    Hiromura, K.
    Nojima, Y.
    Araki, T.
    Nakamura, T.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 67 - 67
  • [35] TREATMENT OF REFRACTORY, SYSTEMIC LUPUS-ERYTHEMATOSUS ASSOCIATED THROMBOCYTOPENIA WITH INTERMITTENT LOW-DOSE INTRAVENOUS CYCLOPHOSPHAMIDE
    ROACH, BA
    HUTCHINSON, GJ
    ARTHRITIS AND RHEUMATISM, 1993, 36 (05): : 682 - 684
  • [36] BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
    Wang, Weijia
    He, Shanzhi
    Zhang, Wenli
    Zhang, Hongyu
    Destefano, Vincent M.
    Wada, Masayuki
    Pinz, Kevin
    Deener, Greg
    Shah, Darshi
    Hagag, Nabil
    Wang, Min
    Hong, Ming
    Zeng, Ronghao
    Lan, Ting
    Ma, Yu
    Li, Fugui
    Liang, Yingwen
    Guo, Zhencong
    Zou, Chanjuan
    Wang, Mingxia
    Ding, Ling
    Ma, Yupo
    Yuan, Yong
    ANNALS OF THE RHEUMATIC DISEASES, 2024,
  • [37] SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN SYSTEMIC SCLEROSIS: RESULTS FROM THE OPEN-LABEL PERIOD OF THE PHASE 3 FOCUSSCED TRIAL
    Khanna, D.
    Lin, C. J. F.
    Spotswood, H.
    Siegel, J.
    Furst, D.
    Denton, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 390 - 390
  • [38] An open-label phase IIa trial assessing the pharmacokinetics, safety and efficacy of dupilumab in a paediatric population with moderate-to-severe atopic dermatitis
    Cork, M. J.
    Thaci, D.
    Davis, J. D.
    Zhang, Q.
    Akinlade, B.
    Graham, N. M. H.
    Pirozzi, G.
    Bansal, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 : 155 - 155
  • [39] An open-label phase IIa trial assessing the pharmacokinetics, safety and efficacy of dupilumab in a paediatric population with moderate-to-severe atopic dermatitis
    Cork, M. J.
    Thaci, D.
    Davis, J. D.
    Zhang, Q.
    Akinlade, B.
    Graham, N. M. H.
    Pirozzi, G.
    Bansal, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 : 67 - 68
  • [40] Tocilizumab in Systemic Lupus Erythematosus Data on Safety, Preliminary Efficacy, and Impact on Circulating Plasma Cells From an Open-Label Phase I Dosage-Escalation Study
    Illei, Gabor G.
    Shirota, Yuko
    Yarboro, Cheryl H.
    Daruwalla, Jimmy
    Tackey, Edward
    Takada, Kazuki
    Fleisher, Thomas
    Balow, James E.
    Lipsky, Peter E.
    ARTHRITIS AND RHEUMATISM, 2010, 62 (02): : 542 - 552
12345